SecBot SecBot
8-K ·Filed Aug 10, 2026

TELA

TELA Bio, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001104659-26-093371
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The guidance withdrawal is the most significant signal, it removes the forward anchor for the stock and implies management sees material downside risk to prior expectations. With cash burning rapidly ($20.4M in H1 2026) and the company still deeply unprofitable, watch for a potential capital raise or restructuring announcement in the coming months. The new CEO's strategic review could lead to asset sales or a reverse merger.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.7900
T+0 close · Aug 10, 2026 · via day close
Latest settled
+6.05%
T+60 · $0.8378
Vs SPY
+6.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $0.7900entry
  2. T+1 · 3mo ago −8.84%α −9.09% · $0.7202
  3. T+5 · 3mo ago −18.61%α −18.20% · $0.6430
  4. T+20 · 2mo ago +15.35%α +16.41% · $0.9113
  5. T+60 · 13d ago +6.05%α +6.54% · $0.8378
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consensus estimates of -$0.18. The company withdrew its full-year 2026 revenue guidance, citing a decline in OviTex PRS volumes and ongoing price/mix headwinds. A new CEO was appointed, but the guidance withdrawal and revenue miss signal significant near-term uncertainty and deteriorating fundamentals for this $39M market-cap medical device company.

Key Financial Metrics

EPS
−$0.20
est −$0.18 · -11.1%
Revenue
$19.3M
est $20.0M · -3.5% · -4.5% YoY
Rating
strong miss
Gross Margin
72.3%

Key Facts

  • Revenue declined 4% YoY to $19.3M, missing consensus of $20.0M
  • EPS of -$0.20 missed consensus of -$0.18 (-12.4% miss)
  • Full-year 2026 revenue guidance withdrawn, citing OviTex PRS volume decline and competitive bundling pressures
  • Net loss widened to $11.3M from $9.9M in the prior-year quarter
  • Cash burn continues: cash dropped to $30.4M from $50.8M at year-end 2025
  • New CEO Heather Getz appointed August 4, 2026, signaling a strategic review

Financial Impact

Revenue miss of ~$0.7M vs consensus; guidance withdrawal removes forward visibility for a $39M market-cap company

revenueepsguidancecash

Risk Factors

  • Further revenue deterioration in H2 2026 as OviTex PRS headwinds persist
  • Cash runway concern: $30.4M at current burn rate (~$11M/quarter) provides ~9 months of liquidity
  • Potential dilutive equity offering to extend runway
  • Competitive bundling from larger players could continue pressuring market share and pricing

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-093371
Document: tm2622768d1_8k.htm0001104659-26-093371
Document: 0001104659-26-093371-index-headers.html0001104659-26-093371
Document: 0001104659-26-093371-index.html0001104659-26-093371
Document: 0001104659-26-093371.txt0001104659-26-093371
8-K Data (Synthetic)0001104659-26-093371

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026